Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AVITA Medical (RCEL) Income towards Parent Company (2018 - 2025)

AVITA Medical (RCEL) has disclosed Income towards Parent Company for 7 consecutive years, with -$11.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income towards Parent Company fell 123.15% year-over-year to -$11.6 million, compared with a TTM value of -$48.6 million through Dec 2025, down 72417.91%, and an annual FY2025 reading of -$48.6 million, down 72417.91% over the prior year.
  • Income towards Parent Company was -$11.6 million for Q4 2025 at AVITA Medical, up from -$13.2 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $50.2 million in Q4 2024 and bottomed at -$18.7 million in Q1 2024.
  • Average Income towards Parent Company over 4 years is -$2.0 million, with a median of -$9.7 million recorded in 2022.
  • Peak annual rise in Income towards Parent Company hit 35.56% in 2025, while the deepest fall reached 123.15% in 2025.
  • Year by year, Income towards Parent Company stood at $29.2 million in 2022, then grew by 28.74% to $37.6 million in 2023, then soared by 33.39% to $50.2 million in 2024, then crashed by 123.15% to -$11.6 million in 2025.
  • Business Quant data shows Income towards Parent Company for RCEL at -$11.6 million in Q4 2025, -$13.2 million in Q3 2025, and -$9.9 million in Q2 2025.